ERBB2 and breast carcinoma: These results suggested that HER2-STAT3-survivin signaling is a key factor in the radioresistance of HER2-positive breast cancer cells, implying that the HER2-STAT3-survivin axis could be a potential target for adjuvant radiotherapy in HER2-positive breast cancers.